

September 11, 2017
Market Strategies Newsletter
Subscriber Members Issue



**Balanced Investing Strategies To
Make Money In Up Or Down Markets**

**MARKET STRATEGIES
NEWSLETTER**

A Publication of Princeton Research, Inc. (www.PrincetonResearch.com)
Contributing Staff: Michael King, Charles Moskowitz

Investing Trade Alerts
Charles Moskowitz Discussion

No Closed Trades For The Week

2017 YTD Profits \$ 12,806

Over 128% Returns

Open Positions:

Long 4 IWM September 138 Calls
Long 3 CSTM Sept 10 Calls
Long 8 SKYW Sept 40 Calls
Long 8 XRT Sept 39.50 Calls
Long 8 ALB Sept 120 Calls
Short 4 IWM September 140 Calls

Funds in Use = \$ 1544

Week 36 was unusual in that we had no closing trades. YTD gains are unchanged at +128% and we have 6 open positions using \$1,544.

Several weeks ago I put out a *special report* about what happens when a group of stocks get ahead of themselves in the short or intermediate terms. The group was the “FAANG” stocks. Since that time a couple have had problems and some are having a very tough time. AMZN is up 300% from early 2015, GOOGL up 200%, and NFLX +400% while the S&P500 and the DJIA are 25% higher. However, since its reversal in July AMZN has fallen 14% and has been unable to rally back 50%, a normal expectation in a bullish market. GOOGL made a new all-time high in June, had a decline and failed to break out and left a double top in July. While its decline is only about 10%, it too has had trouble at the 50% retracement levels. NFLX has only declined 14% and closed Friday at almost exactly a 50% retracement. AAPL and FB are still right up against new highs. The issue isn’t a failure and break to new lows, but rather underperformance vs. other stocks and sectors. These stocks have had massive moves and if we have any more declines may be subject to the institution liquidation for their yearend performance calculations at the close on October 31st.

Now we’ll see how much Harvey and Irma impact the economy. These dramatically fierce storms are unprecedented in their size and power and while there will be a rebuilding phase it won’t be swift. The FEMA involvement is more a recovery at this point and the rebuilding stage is well into the future. The residents will first have to get back to their homes and power will have to be restored before anything can even begin. Here in Boston, 1250 miles north the news is National Grid sending workers to Florida to help out. Insurance stocks will likely be hard hit on Monday, but in the end, they will raise rates based on these storms. I will sit aside that sector until things become clearer. Stocks like HD and LOW will clearly benefit as well as the lumber and materials companies. USG is one of my favorites but CBI, EXP and WY should also register gains in business. We bought 1000 GV, a utility construction company in Melbourne, Florida and paid \$4.27 for it. I might have gone heavier but its location scared me a little.

The only new order this week is in UTX. Follow the Texting service for any changes in our current positions and if we are higher be sure to use the 100% Up Rule triggers as well as the 50% Down Rules. And be ready to pay up for your morning OJ...**CAM**

Investing Trade Alerts Summary **\$10,000 Trading Account Trade Table**

DATE	TRADES	PRICE	COST	PROCEEDS	RESULTS
09/05	Bought 8 ALB September 120 Calls	0.80	640		
09/05	Bought 8 XRT September 39.50 Calls	0.54	432		
08/31	Sold Short 4 IWM September 140 Calls	1.22		488	
08/28	Bought 4 IWM Sept 138 Calls	1.20	480		
08/23	Bought 3 CSTM September \$10 Calls	0.80	240		
08/08	Bought 8 SKYW Sept \$ 40 Calls	0.30	240		

3rd Week expiration when the month is listed without a date

Previous closed out trades not listed here may be seen in previous market letters in the VIP Subscribers Members Area.

Remember, these trades are based on your participation in the

Subscriber Members Only
TEXTING SERVICE TO RECEIVE ALL UPDATES.

NOTE: In texting we have a limited amount of words. In the interest of brevity:

The Quantity and Strike Price for each trade is specific. 1=January, 2=February

Trading is hypothetical. We may trade weekly options and they are noted: SPY 1/25 147 for SPY Jan 25th 147 Calls or Puts.

New Trades Will Be TEXTED To MEMBERS

This is a Sample of the Where To Invest Now Newsletter
Information Our Members Get

Proven Trading Success

TRADE LIKE THIS:

175% Profits on SPY Puts in 3 Days
57% Profits on JBLU Calls in 8 Days
100% Profits on SPY Puts in 1 Day
163% Profits on SPY Calls in 2 Days
20% Profits on AGQ Calls in 15 Days
89% Profits on SPY Calls in 1 Day
130% Profits on GS Calls in 9 Days
217% Profits on XOM Calls in 9 Days
105% Profits on XOM Calls in 3 Days
117% Profits on GLD Calls in 3 days
62% Profits on XOM Calls in 20 days
50% Profits on PFE Calls in 2 Days
31% Profits TWTR Calls in 2 Days
316% Profits on MOS Calls in 13 Days
87% Profits on AMZN Calls in 2 Days
96% Profits on K Calls in 17 Days
16% Profits on HOG Calls in 8 Days
163% Profits on SJM Calls in 23 Days
102% Profits on AMBA Calls in 7 days
250% Profits on WTW Calls in 1 Day
128% Profits on WTW Calls in 1 Day
148% Profits on NVDA Puts in 2 Days

See all trades in past newsletter issues.

**Remember, these trades are based on your participation in the
Subscriber Members TEXTING SERVICE.**

New Trades Will Be TEXTED To MEMBERS

TRADE ALERTS

**For Free Where To Invest Your Money Now
High Return Investments Trade Alerts
Go To: PrincetonResearch.com/alerts.htm**

SPECIAL RATES Available for VIP MEMBERSHIP

Get the [lowest full membership rates available.](#)

**NOTE: This is a Sample Issue Only!
TO GET OUR TRADE ALERTS BY TEXT MESSAGE AND
THE COMPLETE VIP MEMBERS ONLY MARKET STRATEGIES NEWSLETTER ISSUES
Visit: PrincetonResearch.com/join.htm**

Follow Our Marketed Weathered, Time Tested Trading Rules That PROTECT YOUR CAPITAL And SECURE PROFITS

Now you can profit from investing trade alerts from our traders with over 75 combined years of successful investing experience.

- **Make Money In Up Or Down Markets** -- Our trading alerts balanced investing strategies are designed and proven to make money in up or down markets.
- **Done For You** - All the stock options picking, research and trading analysis is done for subscribers. This is not a 'class' or a 'training course'... this is us doing ALL the work... from research to sending you a text on what to trade, along with recommended amounts...
- **SAFETY** - We strictly follow our **Tested, Market Weathered Trading Rules** that are proven time and time again to protect our (and now your) investment capital from losses while effectively allowing us to **Keep The Profits We Make.**

So even though we trade options to get the profits you see above -- We can do it with minimal risk and Maximum Profit Potential.

You Don't Need To Learn Any Trading Skills Or Do Any Time Consuming Analysis and Tracking

+++ We DO IT ALL FOR YOU! +++

We tell you where, when and how much to trade and you get to sit back and enjoy the rewards!

The specific buy and sell trading alerts are sent directly to you by e-mail and text message. So you can get in on and cash out on our winning trades fast and at the right time.

Get Started with Any Amount - Follow our recommended trading guidelines for a \$10,000 portfolio or invest more or invest less -- Whatever you are comfortable with. Your investment is protected because Time Tested Trading Rules PROTECT YOUR CAPITAL And KEEP YOUR PROFITS.

Join Us Today.

Lock in the [Lowest Membership Rates Available HERE](#)



2 FOR 1 BONUS:

Your Membership includes access to both:

**Trade Alerts by Text Message and e-mail
AND
The Market Investing Strategies Newsletter
Full Members Only Edition**

Our Where To Invest Now For Profits In Up or Down Markets Newsletter is more compact, informative, effective and quicker to read then the major, big name publications. AND there are NO ADS to wade through.

The Members Edition Newsletter is sent to you by e-mail Monday Mornings and available in the Members Area along with our archive of past issues.

SPECIAL RATES Available for VIP MEMBERSHIP

Get the [lowest full membership rates available.](#)

MARKET LABORATORY – WEEKLY CHANGES

Prices are copied from [Barron's Weekly](#) and [Yahoo Finance](#) and may be incorrect.

Dow 21,797.79 -189.77 -0.86%	Nasdaq 6360.19 -75.14 -1.17%	S&P 500 2461.43 -15.12 -0.61%	Transportation 9383.74 +27.72 +0.30%	Russell 2000 1399.43 -14.14 -1.00%	Nasdaq100 5913.37 -74.53 -1.24%
Gold (spot) 1346.00 +21.50 +1.6%	Silver Sept 18.123 +0.313 +1.8%	Crude Aug 47.48 +0.19 +0.4%	Heating Oil 1.7657 +0.189 +10.6%	Unleaded Gas 1.6476 - 0.103 -5.9%	Natural Gas 2.89 -0.19 -6.2%
VIX 12.12 +1.99 +16.4%	Put/Call Ratios S&P 100 156/100's +57/100's	Put/Call Ratios CBOE Equity 63/100's +6/100's	Bonds 157-09 +2-03 2.95% 0-024%	10 Yr. Note 127-16+0-25 2.26%-030%	Copper 3.118 +0.06 +2.0%
CRB Inflation Index 181.17 +0.22 +0.1%	Barron's* Confidence 75.6 -1.4	S&P100 1086.98 -8.27 -0.76%	5 YR Note 118-267 -0+14 1.79%-0.05%	Dollar 91.33 -1.48 -1.6%	DJ Utilities 746.94 +5.99 +0.81%
AAll Confidence Index Average	Bullish 29.3% +4.3% 38.4%	Bearish 35.7% -4.2% 30.30%	Neutral 35.0% -0.1% 30.96%	M1 Money Supply +7.42% Aug 28th	M2 Money Supply +4.82% Aug 28th

* Component Change in the Confidence Index

M1...all money in hands of the public, Time Deposits Traveler's Checks, Demand Deposits

M2.. adds Savings and Money Market Accounts both compared with the previous year.

Market Strategies Technical Information

SUPPORT**RESISTANCE**

S&P 500	2446	2491
NASDAQ (QQQ)	143.00	147.20
Trans	92.40	9590
DOW	21,610	22,179
TLT	125.20	129.70

\$100,000 Trading Portfolio Stock Positions and Trades

Each stock is allocated a theoretical \$ 5,000 share of the portfolio unless otherwise indicated.

Symbol	Purchase Price	Purchase Date	Stop/Loss		Price/Date Sold		Profit/ (Loss)
GV 1000	4.27	09/05					
LABU 150	65.76	08/28					
BBRY 400	11.21	06/07					
GLYC 400	12.66	06/01					
HL 500	5.72	06/01					
GSAT 1500	2.30	05/18					
SLV 300	15.78	05/15					
AGQ 150	40.39	04/07					
NUGT 75	35.68	03/13					
RWM 100	50.60	11/21					
SPXU 200	22.88	11/14					
AMBA 100	63.75	10/13					
MOS 200	27.53	05/02					
EYES 500	5.04	04/04					
EYES 1000	6.49	12/28					
TWTR 200	28.51	10/28					
MOS 100	43.55	08/14					
HL 500	3.95	05/03					
SAN 600	8.40	12/16					
TEXQY 200	6.56	7/11					
REPR* 5000	0.22	10/22/12					

Recommendations will be both listed in this letter and texted to members.

Previous closed out stock and option positions can be found in past Market Strategies Newsletter issues available in the VIP Subscribers Members Area.

For those of you who do not buy puts to protect your portfolio, there are many ETF's that are the inverse of the DOW. The symbols are **DOG, DXD, SDS, TZA and RWM**, which go up when the DOW, S&P 500 and Russell 2000 go **down and down when they go up. The DZZ goes up double when gold goes down.**

Market Strategies \$100,000 Trading Account

There were no closed out options positions last week. There were no closing stock trades:
The one new position is the 1,000 shares of Goldfield Corp bought at \$ 4.27, requiring new funds of \$4,270.

There are five remaining long option positions,
the 15 SKYW September \$40 Calls bought at \$ 0.30 costing \$450.00
the 6 remaining CSTM September \$ 10 Calls bought at \$ 0.80
8 IWM Sept 138 Calls bought at \$ 1.20
16 XRT September \$ 39.50 Calls bought at \$ 0.54 and
16 ALB Sept \$ 120 Calls bought at \$ 0.80

The total margin requirement for options is \$ 3,058.

The options expire on the third Friday of each month unless otherwise posted.

The Stock table has the following 19 positions:

AGQ, BBRY, EYES (2), GLYC, GSAT, HL(2), MOS (2), NUGT, REPR, RWM, SAN, SCO, SLV, SPXU, TEXQY, TWTR

The options call for a \$ 2,500 investment unless otherwise stated; each stock position requires \$5,000 unless otherwise mentioned specifically.

Money management is based on a hypothetical \$ 100,000.

The 19 stock positions would cost \$ 79,338.

The Goldfield shares (GV) added last week increases the stock margin requirement by \$ 5.430 to \$ 93,472.

The open long options positions; the SKYW September \$ 40 Calls require \$ 450.

the 6 CSTM Calls need \$ 480,

while the requirement for the 8 IWM Sept 138 Calls 170 Calls is \$ 960

the 16 XRT September \$ 39.50 Calls need \$ 864

and the 16 ALB Sept \$ 120 Calls require \$ 1280 which totals \$ 4,034.

The short IWM Sept 140 Calls provide a credit of \$ 976.

The net comes to a requirement of \$ 3,058

when combined with the stock requirement of \$ 93,472

equals \$ 96,530 which leaves excess cash of \$ 3,470.

YEAR TO DATE the \$100,000 Account has had 148 closed out trades between stocks, options and covered writes versus stock positions.

There were no closed stock positions last week.

There was an improvement in open trade equity (+ \$ 3,053) on the open positions to a minus \$ 17,241.

On the former closed positions, 101 were gains and 47 were losses.

Gains to date equal \$53,215. Losses equal \$18,689, for a net gain of \$34,526.

This number does not take into consideration commissions or open gains or losses.

These figures are approximate and there might be errors.

The trading is hypothetical and we do not count commission costs.

Executions that have occurred at or near the open or close of trading sometimes vary from our actual numbers. For example, when something opens down and it is through our price, we take the next trade whether it is an uptick or continues lower. This sometimes results in a 50% trade that is slightly above or below the exact number.

Previous Week's Recommendations and Rules for the Market Strategies \$100,000 Portfolio Trading Account

- All options count for about \$ 2,500.00 for model portfolio calculations unless otherwise stated
- When the option has doubled sell half the position
- Stop Loss protection is either half or offered with each trade
- The cost of the option is the asking price (or the price between the bid and ask, whichever is more realistic)
- The options will be followed until closed out.
- Option Symbols are stock symbol with expiration month and strike price

Option	Cost	Date	Sold	Date	Profit/ (Loss)
ALB Sept 120 16 lots	Calls 0.80	09/05/17			
XRT Sept 39.50 16 lots	Calls 0.54	09/05/17			
IWM Sept 138 8 lots	Calls 1.20	08/28/17	2.40 Sold Half 8 lots 100% up Rule	08/31/2017	\$ 960
IWM Sept 140 8 lots Short	Calls		1.22	08/31/2017	\$ 976 Credit
CSTM Sept 10 6 lots	Calls 0.80	08/23/17	1.60 Sold Half 6 lots 100% up Rule	08/31/2017	\$ 480
SKYW Sept 40 15 lots	Calls 0.30	08/08/17			

Recommendations will be both listed in this letter and texted to members.

Previous closed out stock and option positions can be found in past Market Strategies Newsletter issues available in the VIP Subscribers Members Area.

This Weeks' Economic Numbers Earnings Releases and Media Data

Before the Open on top of the Row;
After the close below the Economics Information

MONDAY	<p>Anniversary of the 9/11 attacks</p> <p>Investors Real Estate Trust IRET (0.09 vs 0.12) Layne Christensen LAYN (-0.14 vs -0.21) Limoneira LMNR (0.54 vs 0.71) Perigrine Pharma PPHM (NA vs -0.05)</p>
TUESDAY	<p>Eros International EROS (0.00 vs 0.03) ReneSola SOL (-0.76 vs 0.05)</p> <p>Apple unveils the iPhone 8 at an event in Cupertino, California 10:00 hrs Factory Orders July (-3.2% vs +3.0%) Small Business Optimism index for August is reported</p> <p>Farmer Bros Co FARM (0.15 vs 0.23) Hill International HIL (0.01 vs 0.03) Radiant Logistics RLGT (0.03 vs 0.06)</p>
WEDNESDAY	<p>Applied Genetic Technologies AGTC (-0.02 vs 0.15) Cracker Barrel CBRL (2.19 vs 2.12)</p> <p>A Food and Drug Administration advisory panel weighs in on GlaxoSmithKline Biologicals' vaccine. 07:00 hrs MBA Mortgage Applications Index 09/02 (NA vs -2.3%) 08:30 hrs GDP 08:30 hrs Trade Balance July (-44.6 Bln vs -\$ 43.6 Bln) 08:30 hrs PPI August (+0.3% vs -0.1%) 10:00 hrs ISM Services August (+55.2 vs 53.9) 10:30 hrs Crude Inventories 09/02 (NA vs -5.4Mln) 14:00 hrs Fed's Beige Book release September (NA) Lakeland Industries LAKE (0.20 vs 0.20) Sparten Corporation SPA (0.12 vs 0.50) United Natural Foods UNFI (0.70 vs 0.70)</p>
THURSDAY	<p>ARC Group ARCW (-0.05 vs -0.04)</p> <p>The Bank of England meets and issues its decision on interest rates. 08:30 hrs Productivity- Revised 2nd Qtr (+ 1.2% vs +0.9%) August Consumer prices are released: 08:30 hrs CPI August (+ 0.3% vs + 0.1%) 08:30 hrs Unit Labor Costs - Revised 2nd Qtr(0.3% vs 0.6%) 08:30 hrs Initial Claims 09/02 (239K vs 236K) 08:30 hrs Continuing Claims 08/26 (NA vs 1942K) 10:30 hrs Natural Gas Inventories) 09/02 (NA vs 30bcf) 15:00 hrs Consumer Credit July (\$ 15.0Bln vs \$ 12.4 Bln)</p> <p>Electronics for Imaging EFII (0.56 vs 0.56) Oracle ORCL (0.60 vs 0.55) S&W Seed SANW (-0.02 vs 0.08)</p>

FRIDAY

08:30 hrs Retail Sales August (0.1% vs 0.6 %)
08:30 hrs Retail Sales ex-auto August (0.5% vs 0.5%)
08:30 hrs Empire Manufacturing September (20.0 vs 25.2)
09:15 hrs Industrial Production August and Cap Utilization
10:00 hrs Wholesale Inventories July (0.4% vs 0.7%)

The U.S. Oil Rig Count remained constant at to 759. The Nat Gas Rig count remained at a total of 184, there were no miscellaneous rigs, making a total rig count **943**. There are 452 more rigs in operation this year, up from 2016. Crude closed slightly higher at \$47.48 gaining \$ 0.19 or + 0.4%. Natural Gas closed the week falling \$ 0.19 or -6.2% at about \$ 2.89.

Market Strategies Fundamentals

The Dow Jones Industrials (21,797.79 -189.73 or - 0.86%) made a mirror-image reversal of the previous week losing all of its gains. There were continued geopolitical tensions with North Korea, declining confidence in the feasibility of tax reform and the typical seasonal down period of September which typically weighs on investor sentiment. As the historically difficult month of September materializes, it becomes miraculous that stocks have held elevated levels. Blue chip stocks like Home Depot (HD: \$ 159.47) + 8.69 or + 5.8%; Exxon (XOM: \$ 78.78) + 2.21 or + 2.9% and Pfizer (PFE: \$ 34.15 + 0.19 or + 0.6%) were steady enough to prevent a rout.

The S&P 500 (2461.43) - \$ 15.12 or - 0.61% was the best performing index off just 15 points or (- 0.61%) The index finished Friday's session just 0.8% below its record-high close of 2,480.91.

The Nasdaq Composite (6360.19) - \$ 75.14 or - 1.17% were led down by the big chip makers like Qualcomm (QCOM: \$ 49.53) - \$ 2.52 or - 4.8%; NVIDIA (NVDA: \$ 162.89) - \$ 7.57 or -4.4%; the Van Eck Semiconductor ETF (SMH: \$ 87.39) - \$ 1.61 or - 1.8%;

The Dow Jones Transportation Average (9383.74) + \$ 27.72 or +0.30% was the leader, the best performing index last week after being the worst the previous three weeks crashing to its 200-day price moving average. The Dow Jones Transportation Index Fund reversed (IYT: 169.16) + \$ 0.52 or +0.3% refused to be pulled down by weakness in other markets.

Index	Started Week	Ended Week	Change	% Change	YTD %
DJIA	21987.56	21797.79	-189.77	-0.9%	10.3
Nasdaq	6435.33	6360.19	-75.14	-1.2%	18.2
S&P 500	2476.55	2461.43	-15.12	-0.6%	9.9
Russell 2000	1413.57	1399.43	-14.14	-1.0%	3.1
DJT	9356.02	9383.74	+27.72	0.3%	3.8

US Dollar (DXYO: 91.52 - \$ 1.31 or -1.4% . The dollar was weak making new lows for the year.

Volatility (VIX: \$12.12 + 1.99 or +16.4%) The volatility was strong picking up from the weakness of the previous week surging above its 50 day m.a. and challenging its 200 day m.a. just above at 11.11.

CBOE OEX Volatility Index (VXO-X 11.11) + 2.17 or +24%% Reversed completely, challenging to close above its 200 day price moving average.

The UVXY, (\$ 31.61) + \$ 2.67 or + 9.2% appears to be claiming higher levels which would be a headwind for stocks.

The U.S. Oil Fund (USO : \$9.73 + 0.06 or +0.6%) struggling to hold its 13 and 50 day moving averages as the market works off huge supplies; goes into seasonal downtrend..

Semiconductors (SMH: \$ 87.39) -\$ 1.61 or - 1.8% Profit-taking after it rallied to almost the 2017 high reached June 8th at \$ 89.72.

Natural Gas (2.89 -0.19) U.S. natural gas prices fell slightly recovering from the hurricane Harvey induced rally as the market faces huge supplies.

Russell 2000 (IWM: \$ 139.21) -1.31 or -0.9%: Found resistance at the 50 day moving average. Small-cap companies generally underperformed.


The GDX, the VanEck Gold Miners ETF (GDX: 25.24) + 0.46 or +1.9% Continued its ascent after breaking above and finding support at the 200-day m.a. It is now less than a half dollar from its yearly high of \$ 25.71.

Alibaba (BABA: \$ 168.99) - \$ 2.05 or -1.2%; Fell slightly induced by other markets. It remains one of the strongest stocks and solidly bullish. Our original buy recommendation on April 11th was \$ 111.00/share.

Amazon (AMZN: \$ 963.68) -14.57 or -1.5%: Climaxed at \$1083.31 and since dropped 140 points during the past three weeks possibly seeking a new direction.

Crude OIL (\$47.48) +0.19 + 0.4% The strong world economy is supportive in utilizing huge supplies.

Gold (GLD: \$ 128.09 +\$ 2.03 or +0.2% Found new support at the \$ 120.50 level and then rallied impressively remaining above all moving averages moving well above the year's highs achieved June 7th. It looks impressive in all major currencies. Fed uncertainty has helped firm up gold prices, while popularity of gold has plummeted in China and India. But despite this massive decline in the largest single source of gold demand, prices have proved resilient, partly due to strong investor demand; also, in the face of the world-wide political instability, plus the delay of interest-rate hikes by the US.



Market Strategies Economic Data



The Trade Deficit for July at -\$43.7 billion was better than expected as most including Briefing.com expected a -\$44.6 billion number. On a month-over-month basis, the trade deficit widened a tad from an upwardly revised deficit of \$43.6 billion for June. The drop in imports was led by a 0.9% decline in imports of automotive vehicles, parts and engines.

The month-over-month widening in the deficit was the result of exports being \$0.6 billion less than June exports and imports being \$0.4 billion less than June imports

The drop in exports was paced by a 0.7% decline in exports of consumer goods and a \$0.6 billion decline in exports of automotive vehicles, parts and engines.

The key takeaway from the report, however, is that it should compute favorably for Q3 GDP forecasts considering the real trade deficit for July (\$61.6 billion) was 1.3% below the second quarter average.

Category	JUL	JUN	MAY	APR	MAR
Trade Deficit	-\$43.7B	-\$43.5B	-\$46.4B	-\$47.4B	-\$44.8B
Exports	\$194.4B	\$194.9B	\$192.3B	\$191.6B	\$192.2B
Imports	\$238.1B	\$238.5B	\$238.7B	\$238.9B	\$237.0B



The ISM Non-Manufacturing Index increased to 55.3 in August (Briefing.com consensus 55.2) from 53.9 in July, marking the 92nd straight month the index has been above 50.0, which is the dividing line between expansion and contraction. The New Orders Index increased from 55.1 to 57.1. The Employment Index increased from 53.6 to 56.2. The Prices Index increased from 55.7 to 57.9. The Backlog of Orders Index increased from 52.0 to 53.5.


According to the ISM, the past relationship between the index and the overall economy indicates the reading for August corresponds to a 2.5% increase in real GDP on an annualized basis

The Inventories Index was the biggest drag, slipping from 56.5 to 53.5

The key takeaway from the report -- other than the important services sector remains in an expansion mode -- is that the uptick in July was paced by an increase in new orders and more employment.

Category	AUG	JUL	JUN	MAY	APR
Non-Manufacturing ISM index	55.3	53.9	57.4	56.9	57.5
Business Activity	57.5	55.9	60.8	60.7	62.4
New Orders	57.1	55.1	60.5	57.7	63.2
Employment	56.2	53.6	55.8	57.8	51.4
Deliveries (nsa)	50.5	51.0	52.5	51.5	53.0

Inventories (nsa)	53.5	56.5	57.5	54.0	52.5
Exports (nsa)	55.0	53.0	55.0	54.5	65.5
Imports (nsa)	50.5	51.5	51.0	48.5	53.0
Prices Paid	57.9	55.7	52.1	49.2	57.6



Source: Institute for Supply Management; updated 09/06/17

Briefing.com

Personal Income increased 0.4% in July. The Briefing.com consensus expected +0.3%, led by a nice 0.5% increase in wages and salaries, while personal spending increased 0.3%. The Briefing.com consensus expected a +0.4% increase on the heels of an upwardly revised 0.2% increase from 0.1% for June. The personal savings rate dipped from 3.6% to 3.5%.


The PCE Price Index and core PCE Index, which excludes food and energy, were both up 0.1% in July. Those increases left the PCE Price Index up 1.4% year-over-year, unchanged from the 12-months ending in June, and the core PCE Price Index up 1.4%, down from 1.5% in June.

The key takeaway from the report was that inflation pressures remained subdued, which suggests to market participants that expectations for another rate hike this year can also remain subdued.

Category	JUL	JUN	MAY	APR	MAR
Personal Income					
Total Income	0.4%	0.0%	0.3%	0.1%	0.3%
Wage and Salary	0.5%	0.5%	0.1%	0.6%	0.1%
Disposable Income	0.3%	0.0%	0.4%	0.2%	0.3%
Savings Rate	3.5%	3.6%	3.8%	3.7%	3.9%

Personal Consumption

Total (Nominal)	0.3%	0.2%	0.2%	0.3%	0.5%
Total (Real, Chain \$)	0.2%	0.2%	0.3%	0.1%	0.7%
Core PCE Deflator					
Month/Month	0.1%	0.1%	0.1%	0.2%	-0.2%
Year/Year	1.4%	1.5%	1.5%	1.6%	1.6%



Market Strategies Cycles

Crude Oil tends to make its most significant price gains in the summer, a seasonal expectation, as vacationers and the travel necessitated by students returning to college in August-September, creates increased demand for unleaded gasoline. The market can also price in a premium for supply disruptions due to threats of hurricanes in the Gulf of Mexico. However, towards September and October, we often see a seasonal tendency for prices to peak out, as both the driving and hurricane seasons begin to wind down. Crude oil's seasonal decline is highlighted in yellow in the following chart.



Shorting the February crude oil futures contract in mid-September and holding until on or about December 10 has produced 22 winning trades in the last 34 years. This gives the past trades a 64.7% success rate and theoretical total gains totaling all the gains minus losses of \$101,920 per futures contract. Following three consecutive years of losses, this trade has been successful in four of the last five years.

It has been over three years since crude last traded above \$100 per barrel. Ample supply and inventories have largely keep price under \$50 per barrel ever since. Even hurricane Harvey had just a modest impact on the price of crude. Gasoline did spike, but crude did not. Crude's failure to respond might suggest the next move could likely be lower especially as summer driving season demand begins to fade. This year Crude began the summer trading about \$ 44.74, just about \$ 2.50 below current levels.

SEPTEMBER SHORT CRUDE OIL (FEB) TRADING DAY: 8 – HOLD : 62 DAYS

Year	Entry		Exit		Profit/
	Date	Close	Date	Close	Loss
1983	9/13	30.93	12/12	28.98	1,950
1984	9/13	29.65	12/12	26.80	2,850
1985	9/12	26.28	12/11	25.79	490
1986	9/11	14.76	12/10	15.24	-480
1987	9/11	19.00	12/10	18.16	840
1988	9/13	14.51	12/12	15.72	-1,210
1989	9/13	18.88	12/11	20.51	-1,630
1990	9/13	28.11	12/11	25.88	2,230
1991	9/12	21.16	12/10	19.46	1,700
1992	9/11	21.51	12/10	19.38	2,130
1993	9/13	18.11	12/10	15.36	2,750
1994	9/13	17.67	12/12	16.95	720
1995	9/13	17.74	12/12	18.42	-680
1996	9/12	22.23	12/11	22.93	-700
1997	9/11	19.62	12/10	18.41	1,210
1998	9/11	15.20	12/10	11.21	3,990
1999	9/13	22.54	12/10	24.71	-2,170
2000	9/13	31.24	12/12	29.10	2,140
2001	9/18	27.55	12/17	19.52	8,030
2002	9/12	28.05	12/11	27.42	630
2003	9/11	28.01	12/10	31.76	-3,750
2004	9/13	42.42	12/10	41.36	1,060
2005	9/13	65.19	12/12	62.26	2,930
2006	9/13	67.51	12/12	61.99	5,520
2007	9/13	76.05	12/11	89.92	-13,870
2008	9/11	101.94	12/9	44.66	57,280
2009	9/11	71.14	12/9	72.55	-1,410
2010	9/13	80.37	12/9	88.88	-8,510
2011	9/13	90.66	12/9	99.60	-8,940
2012	9/13	99.63	12/11	86.32	13,310
2013	9/12	103.14	12/10	98.66	4,480
2014	9/11	90.95	12/9	63.98	26,970
2015	9/11	47.13	12/9	38.72	8,410
2016	9/13	47.40	12/12	53.75	-6,350
34 -Year Gain					\$101,920
# Wins					22
# Losses					12


SEPTEMBER 2017

Sector Seasonalities: Long = (L); Short = (S)

Start: Oil (S)

In Play: Biotech (L), High-Tech (L), Semiconductor (S),
Utilities (L), Materials (S), Gold & Silver (L), Transports (S)

Finish: None

MONDAY	TUESDAY	WEDNESDAY	THURSDAY	FRIDAY	SAT	SUN
<p>*Tuesdays: Weekly Chain Store Sales & Avg Hourly Earnings *Wednesdays: Oil & Gas Inventories *Thursdays: Wkly Unemployment Report, Wkly Mutual Fund Flows & Weekly Natural Gas Storage Report *Fridays: Weekly Leading Economic Index <i>*Except holidays</i></p>				<p>1 First Trading Day, S&P Up 13 of Last 22</p> <p>Construction Spending ECRI Future Inflation Index Employment Rate ISM Index Semiconductor Billings U Mich Consumer Sentiment Vehicle Sales</p>	2	3
<p>4</p> <p>Labor Day (Market Closed)</p>	<p>5</p> <p>Day After Labor Day, Dow Up 16 of Last 23</p> <p>Factory Orders</p>	<p>6</p> <p>Average September Gains Last 21</p> <p>Dow: -0.7% Up 10 Down 11 Rank #9</p> <p>Beige Book Int'l Trade Deficit ISM Non-Mfg. Index</p>	<p>7</p> <p>S&P: -0.3% Up 11 Down 10 Rank #10</p> <p>Productivity and Costs</p>	<p>8</p> <p>NAS: -0.1% Up 12 Down 9 Rank #10</p> <p>Consumer Credit Wholesale Trade</p>	9	10
<p>11</p> <p> In Memory</p> <p>Monday of Triple Witching Week, Russell 2000 Down 11 of Last 18</p>	<p>12</p> <p></p> <p>Expiration Week 2001, Dow Lost 1370 Points (14.3%), 2nd Worst Weekly Point Loss Ever, 5th Worst Week Overall</p>	<p>13</p> <p></p> <p>PPI Treasury Budget</p>	<p>14</p> <p>CPI</p>	<p>15</p> <p></p> <p>Triple Witching Day, Dow Up 10 of Last 15</p> <p>Business Inventories Industrial Production Retail Sales U Mich Consumer Sentiment</p>	16	17
<p>18</p> <p></p>	<p>19</p> <p>SEMI Book to Bill Ratio Housing Starts Import/Export Prices</p>	<p>20</p> <p>Existing Home Sales FOMC Meeting</p>	<p>21</p> <p>Rosh Hashanah</p> <p>Leading Indicators Philadelphia Fed Survey</p>	<p>22</p> <p></p>	23	24
<p>End of September Prone to Weakness From End-of-Q3 Institutional Portfolio Restructuring Week After September Triple Witching Dow Down 21 of Last 27 Average Loss Since 1990, 1.1%</p>						
<p>25</p> <p></p> <p>NAHB Housing Mkt Index</p>	<p>26</p> <p>Consumer Confidence New Home Sales</p>	<p>27</p> <p></p> <p>Durable Goods</p>	<p>28</p> <p></p> <p>Agricultural Prices GDP - Q2 Final</p>	<p>29</p> <p></p> <p>Last Day of Q3 Dow Down 14 of Last 20</p> <p>Chicago PMI Personal Income/Spending U Mich Consumer Sentiment</p>	30	1
<p>Economic release dates obtained from sources believed to be reliable. All dates subject to change.</p>			<p> Bull symbol signifies a favorable day based on the S&P 500 Rising 60% or more of the time on a particular trading day 1996-2016</p>	<p> Bear symbol signifies an unfavorable day based on the S&P 500 Falling 60% or more of the time on a particular trading day 1996-2016</p>		

Undervalued Small Cap Stocks

Lower priced stocks that look to be a buy:

Lower Capitalized Companies with Great Potential

RMS Medical Products (REPR: \$ 0.51)

RMS Medical Products is the leading manufacturer of medical products used for home infusions and suctioning. The Infusion product portfolio currently includes the FREEDOM60[®] and the latest Freedom Edge[®] Syringe Infusion Drivers, RMS Precision Flow Rate Tubing[™] and RMS Hlgh-Flo Subcutaneous Safety Needle Sets[™]. These devices are used for infusions administered in professional healthcare settings as well as at home. The Company's RES-Q-VAC[®] line of medical suctioning products is used by emergency medical service providers in addition to a variety of other healthcare providers. The Company's website may be visited at www.rmsmedicalproducts.com.

RMS" or the "Company" is pleased to announce the launch of the RMS Freedom Flow Rate Calculator Smart Phone App (available for Android, and iOS). This App is designed to allow customers to more easily configure an RMS infusion system based on the drug being delivered. The App is an easy to use but highly complex calculator which will aid pharmacists, doctors and nurses in determining the proper RMS Precision Flow Rate Tubing[™] and RMS Hlgh-Flo Subcutaneous Safety Needle Sets[™] to be used with either the FREEDOM60[®] or the FreedomEdge[®] Syringe Driver Infusion Systems. Nurses and Pharmacists often make critical decisions about flow rates/tubing and needle selections (size and number of needles to be used for infusion) in order to meet drug delivery protocols and patient desires for time of infusions. This new App will make it very easy to help the patient receive the best care possible.

This RMS Freedom Flow Rate Calculator Smart Phone App was developed for RMS with resources from **ContraCare** GmbH, a leader in Germany for **Contract Management (reimbursement) Services and Managed Care (homecare) solutions**. The App is now available for iOS in the Apple[™] Store and Android in the Google[™] Play store. Just go to your favorite store and type in RMS Freedom and you will be able to find and download this free user friendly app.

Torsten Kühn, Chief Executive Officer of ContraCare, commented "as a premium service provider in Germany's health care system, we aim to partner with leading suppliers to provide the best drugs, medical devices and services to our patients while keeping an eye on the cost efficiency of the treatments we provide. The RMS FREEDOM60[®] system with its durable and reliable syringe driver and high-quality Hlgh-Flo[™] subcutaneous safety needle sets are exactly the products we needed for immunoglobulin, antibiotic and many other therapies we are providing today. We are glad that the umbrella organization of Germany's public health insurance confirms the unmet need by approving the RMS FREEDOM60[®] System for reimbursement."

Eric Bauer, Chief Operating Officer of RMS commented, "It can take 12 to 14 months to obtain country registration; by partnering with a leading health care provider, that time was cut significantly. Contra Care is an exceptional partner and we could not be more pleased with our relationship. Germany is going to be a great market for our high quality products and our ever expanding product line. RMS continues to be the Global industry leader and create exceptional partnerships around the world to improve patient quality of life."

Contra Care GmbH, based in Nuremberg, Germany, is specialized in providing Contract Management (reimbursement) Services and managed Care (homecare) solutions for patients with chronic diseases. The company is certificated in accordance with ISO 9001, ISO 27001, ISO 13485 and licensed as a homecare provider of medical devices and treatment services according to German Social Law (SGB).

Enzo Biochem (ENZ: \$ 11.10) -\$ 0.25 or -2.2%

Enzo Biochem closed the calendar year 2016 at \$6.94 a share. For the year of 2017, it is up 55.3% versus the Dow Jones +9.7%. Enzo's balance sheet closed their first quarter October 31 with \$67 million in cash and current equivalents and complete elimination of debt. Both the Clinical Lab and Life Science divisions ended the year profitably. New products were added to their catalog and litigations have moved ahead leaving them as a plaintiff with 6 lawsuits in the Delaware Court and one in the Manhattan Court. Enzo Biochem closed today, June 30, at \$11.04. For the quarter it was up 31.9% and for the first half it was up 59.08%. The Standard and Poor 500 closed at 2,423 up 2.57% for the quarter and 8.24% for the first half. The stock has been acting great and I hope it continues for the second half of the year.

A quick rundown of the year so far: The Company announced its fiscal 3rd quarter a few weeks ago. For the first time in many years they showed a breakeven third quarter and no cash burn. They actually increased the cash position by \$200,000. I see no reason that this performance will not continue for the rest of the year.

Three new AmpProbe products were announced as being approved by the New York Department of Health with more approvals anticipated over the near future. As was announced in the conference call on June 11th; the Company anticipates a product rollout to the market in early fall. They will expand their market to include New England and the Atlantic States.

With Enzo now being included by Cigna for reimbursement I would expect to start seeing the top line numbers for Revenues ramp up. The Company also hopes to have blanket approval in all states by the end of the year. In the 2nd quarter conference call a question was asked by the Rodman Renshaw analyst about Alequel for treatment of Crohn's disease. The response by Mr. Weiner was that there are discussions with Hadassah Hospital where the trials were held a few years ago. Crohn's and Uveitis are not in the stock price and if any news comes out on either of these products I feel it would have a very positive effect on the price of the stock.

The stock should consolidate its gains over the near term and as product approvals come in and AmpProbe moves into the market, the stock price could move to \$15. Positive news on the Therapeutics could move it much higher. There is very little stock available Institutional ownership is stated to be 61.47% and the Officers, Directors and insiders would be an additional 15% to total 76% of the 46 million shares or 35 million shares leaving 11 million in the float. Enzo's market cap is now over \$500 million which will make more Institutions that have a minimum market cap of \$500 million to be buyers of a stock. Barring any unforeseen events I think we should have a very good second half of the year.

Updates on Delaware Litigation

The last earnings report showed a cash position in excess of \$65 million with no debt to speak of and a positive cash flow from their operating divisions. The only cash burn is coming from Litigation expenses and a bit from Research and Development. Litigation in Delaware is on a contingency basis as such Enzo is not on the hook for billable hours. To my knowledge there are 6 suits left after 6 have settled.

When the company passed the \$ 500 million dollar market cap when the stock price reached (\$10.63) they qualified for those Institutions that can't buy microcap stocks. A significant number of Institutions will look to be buyers and with only 47 million shares issued and Institutions already owning 50% and insiders owning 15% that leaves less than 17 million shares in the float.

Pressure Bio Sciences OTCQB: PBIO 4.00*

Revenues from products sold increased quarter to quarter to \$ 540,372 this year up from \$ 510,963 in 2016, an increase of \$ 29,409 or 6% primarily due to higher revenue from grant related activities and instrument sales. Products and services revenue increased to \$ 480,400 in 2nd Qtr 2017 compared to \$ 474,187 during the same period of 2016.

The company recently announced the signing of a new CFO Mr. Joseph L. Damasio Jr. Mr. Damasio has over 20 years of finance and accounting experience most recently as Finance Director at Nelipak Packaging, a private equity backed medical packaging manufacturer with over \$ 100 million in global annual sales. Before joining Nelipak, Mr. Damasio held financial positions at CP Bourg, IQEKC, and Kopin Corporation. Mr Damasio was employed by Pressure BioSciences as both accounting manager (2007) and controller (2008) and finally as Vice President of Finance and Administration (2011).

The hiring of Mr Damasio will allow the Company's CEO Mr Richard T Schumacher, who has been the company's interim CFO for the past two years, and who has been a successful serial life sciences entrepreneur with three successful publicly traded companies to his credit, time to focus on critical operational issues in 2017. Some issues to be attended to include a pending up-list to NASDAQ and their stated goal to build a field sales team this year.

PBIO Develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated \$6 billion life sciences sample preparation market. Products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions. To date, they have installed over 250 PCT systems in approximately 160 sites worldwide. There are over 100 publications citing the advantages of the PCT platform over competitive methods, many from key opinion leaders.

NEEDS IN MEDICINE: In the world of medicine our dramatically improved ability for early detection or to confirm and refine diagnosis ranging from over a hundred types of cancer to tuberculosis and a hundred other maladies and conditions is "bottlenecked" by 30 year old methods of preparing test samples. Collectively such diagnostic samples exceed a hundred million annually.

NEEDS IN RESEARCH: Globally there are over a half a million medical and pharmaceutical research scientists working in over eighty thousand laboratories who are hampered by the time consuming and outdated methods of preparing test samples.

NEEDS IN FORENSICS: Globally, in millions of cases, swift and sure exoneration of the innocent and / or justice for the guilty is often delayed or even denied because of the ponderous means of preparing and conducting DNA and other forensic testing.

PBIO is focused on solving the challenges of biological sample preparation, a crucial laboratory step performed globally by the biological life sciences research scientists. Sample preparation refers to a wide range of activities that precede most forms of scientific analysis. It is often complex, time-consuming and, in our opinion, one of the most error-prone steps of scientific research. Sample preparation is a ubiquitous laboratory undertaking - the requirements of which drive a large and growing worldwide market. PBIO has developed and patented a novel, enabling technology platform that can control the sample preparation process while improving both efficacy and quality. It is based on harnessing the unique properties of high hydrostatic pressure. This process, called **pressure cycling technology, or PCT**, uses alternating cycles of hydrostatic pressure between ambient (normal atmosphere) and ultra-high levels i.e., 35,000 pounds per square inch ("*psi*") or greater to safely, conveniently and reproducibly control the actions of molecules in biological samples, such as cells and tissues from human, animal, plant and microbial sources.

The PBIO pressure cycling technology uses proprietary and internally developed instrumentation that is capable of cycling pressure between ambient and ultra-high levels at controlled temperatures and


specific time intervals, to rapidly and repeatedly control the interactions of bio-molecules, such as deoxyribonucleic acid (“DNA”), ribonucleic acid (“RNA”), proteins, lipids and small molecules. Their laboratory instrument, the Barocycler®, and their internally developed consumables product line, which include Pressure Used to Lyse Samples for Extraction (“PULSE”) tubes, and other processing tubes, and application specific kits such as consumable products and reagents, together make up their PCT Sample Preparation System (“PCT SPS”).

The PBIO pressure cycling technology takes a unique approach that has the potential for broad use in a number of established and emerging life sciences areas, which include:

- *Biological sample preparation in potentially thousands of research laboratories worldwide working in human, animal, plant, and microbial diseases and disorders - including but not limited to sample extraction, homogenization, and digestion in genomic, proteomic, lipidomic, metabolomic and small molecule study areas;*
- *Pathogen inactivation (useful in vaccine development, infectious disease research, and more);*
- *Protein purification, and in the control of chemical reactions, particularly enzymatic (useful in drug design and development);*
- *and immunodiagnostics (useful in the development and detection of biomarkers).*

INTELLECTUAL PROPERTY

PBIO has secured their technology through fifteen issued United States patents which includes issued foreign patents covering multiple applications of pressure cycling technology in the life sciences field. They also have additional patents pending. Research indicates that Pressure Bio Science, Inc. is the only company globally to have patents in this new science sector.



Leo Motors (LEOM: \$0.14)*

is the premier company that develops electric vehicles (EV's) that can travel at higher speed along roads and freeways. After 10 years of field tests, the Company has surpassed obstacles of speed, torque and reliability over other e-vehicles. Leo motors has developed an array of electric vehicles and boats, including armored military vehicles, sports cars, utility trucks, passenger buses and electronic title water boats.

Leo Motors primary division, LGM, is producing and marketing electric boats (E- boats). LGM is the one of the few companies in the world that produces a safe high power electric boat. March 2017, LGM unveiled their proprietary new electric powerboat propulsion system at the 2017 Busan Boat Show in Korea. The new LGM powerboat electric propulsion system produces up to 660 horse power (HP) and is compatible with most power boats and yachts.

LGM's electric inboard and outboard propulsion systems now range from 40 HP to 700 HP and also includes their Sailing Generation System that uses wind to recharge batteries while under way, eliminating conventional charging processes. LGM is communicating with potential partners in America for their conversion enterprise.

LGM will enter into the U.S. market this year providing electric conversion services. LGM will replace old internal combustion engine yachts and powerboats to the LGM electric power system.

Smart E-Vehicle Technology

LEO's proprietary electronic vehicle ecosystem has intelligent software which controls a cloud system. LEO developed the Vehicle to Everything (V2E) platform which uses smart technology to manage a cloud in the operating system (OS). The integrated OS allows connectivity with a smart device for improved driving solutions. The smart applications help reduce battery exchange recharge time, and provides roadside assistance. A GPS application uses satellite and mobile networks connected to Android systems using a Bluetooth®. The app sends updates, battery status and swap service information.

Skinvisible (SKVI: \$ 0.03)*

Skinvisible Pharmaceuticals, Inc., is a pharmaceutical technology company that has developed over 40 topical prescription (Rx), over-the-counter (OTC) and cosmeceutical products using its patented Invisicare® polymer delivery systems. Invisicare and its products are protected by fourteen patents worldwide. Skinvisible licenses these products to global pharmaceutical, cosmetic and consumer goods companies.

SKINVISIBLE ENTERS THE CANNABIS MARKET

The cannabis market that Skinvisible has entered is vast and one of the fastest growing markets. The legal marijuana industry (medical and recreational) in the USA has reached over \$6 billion in annual sales and is expected to increase to over \$20 billion by 2020. Canada is projected to reach up to \$22 billion annually as it has passed both medical and recreational marijuana laws this past year. Skinvisible is perfectly poised to be a part of this expanding market. It is part of the ancillary cannabis market as Skinvisible does not sell or touch cannabis; it sells its proprietary Invisicare polymers coupled with proven product formulations and services to its licensees. Skinvisible will help bring science-based, patent protected products into this emerging industry. The Company has developed topical and transdermal cannabis products from hemp-derived CBD; with its next developments to include cannabinoids from marijuana (CBD and THC).

SKINVISIBLE RECEIVES FIRST ORDER FOR CHINA

The Company just recently announced that it has completed its first international sale of DermSafe® hand sanitizer through its agent InterSpace Global, Inc. ("InterSpace"). InterSpace is an exporter of "made in USA" products with offices in Salt Lake City, Utah and Shenzhen, China. InterSpace has completed its first sale of DermSafe® with a direct sales company in Shanghai, China. Skinvisible management attended the launch of DermSafe in Shanghai, China, with 1200+ distributors in attendance. China with a population of over 1.4 billion people is one of the fastest growing economies in the world and represents a huge market for Skinvisible products, not only for DermSafe hand sanitizer but also the OTC line of products including anti-aging skincare line.

NightFood, Inc. (NGTF 0.16)*

Has healthy night-time food specially formulated for nighttime snackers. The Company has an exclusive agreement with RFI, natural ingredient manufacturer and proprietor of Chocamine, a patented cocoa extract which helps with cravings and mood (calmness), and promotes feelings of satiety.

Americans keep gaining more weight. People have the tendency to grab for goodies at the end of the evening as they relax to enjoy some T.V. Eating and snacking too late at night is a contributing factor to gaining weight. Seventy percent of adults, ages 18-54, snack in the hour or two before bed. Chocamine delivers the health benefits of chocolate to the body (amino acids, minerals and polyphenols) without the added sugars, caffeine or fat.

People give in to the intense hunger cravings that leads to the consumption of sugary, salty or calorie dense foods to satisfy their appetite and cravings. Most of the snacks that people typically eat can impair sleep, causing a person to wake up feeling unrested. Night Food offers better-for-you alternatives to high-calorie and sleep disruptive junk foods.

The company product line currently includes snack bars in two flavors, either Cookies and Dreams or Midnight Chocolate Crunch. The company recently reported that it is looking into expanding the number of flavors in the Night Food bar line, and also manufacturing products in different snack formats, like ice cream or "bites".

Consumers spend over \$50 billion/year on night-time snacks ... over \$1B every week.

In general, snacking trends have shifted much healthier over the past several years, but industry research continues to show that the least healthy choices of the day occur as we get closer to bedtime. In fact, the four most popular nighttime snack categories, in order, are salty snacks (chips, pretzels, popcorn), ice cream, chocolate candy, and cookies.

Management believes that, just as there are energy versions of many popular foods (energy jerky, energy candy, energy waffles, energy gum, energy chips, energy bars), foods can also be formulated to be more nighttime appropriate and sleep-friendly.

We've seen it happen with low-carb, we've seen it happen with gluten-free.

Fundamental Analysis Stocks To Buy with Stops

Using fundamentals the following are stocks to trade hypothetically. They have done well. We have taken numerous profits as indicated on the table below. In addition some have been stopped out with small losses.

As indicated on the table below, balance is critical. And we have exited most long positions.

Alibaba and Boeing have made a great deal of points. We did take profits. We are looking for a place to re-buy.

We have no position in Alcoa AA. If long, sell on the opening Monday.

Flushing Financial FFIC fell below the 50 day price moving average on March 3rd, and again on August 9th and now has even breached the 200 day m.a. We would buy the Flushing Financial on declines to \$ 25.

We have been looking for a place to buy Bristol Myers.

Hecla Mining might be a speculative buy at a double bottom from July 7th at about \$ 4.82-86.

We took profits on ENZ but still want to be long at lower prices.

The HDGE is a trading vehicle. The recent rally to the 13 day moving average at \$ 8.77 was a reasonable place to sell. The decline to the 50 day m.a. at \$ 8.62 is a buying opportunity. We now look for \$ 8.93. It is a good long or offset against portfolio positions.

Symbol	Name	Business Description	PE	P/S	MV mln	Current Price	Buy or Sell Limit	Stop Loss Or offset
BABA	Alibaba	Largest on-line book seller in China; more of a retailer than Amazon	50.67	13.21	275.5B	168.99	Bought @ \$ 111 on 4/7/17 opening	Profits taken 160 -170
AMZN	Amazon	Catalog & Mail Order	189	2.90	394B	963.68 stopped out	Sold on stop 976	No position See July mkt letters
SIMO	Silicon Motion	Semiconductor solutions for mobile storage and communications	9.7	2.5	1.39B	46.58 Stopped out 49.40	Bought 39.10 01/28/17	49.40x on June 29 th
CIO	City Office REIT	Real Estate Investment Trust high quality Offices	292	5.8	396Mln	12.87	Re Bought at 12.12	Raise stop to 12.28
TPC	Tutor Perini	Construction	12	0.25	1.3B	25.85 Stopped out 28.90 05/04/17	19.40 bought 10/31/16	Looking for place to re-buy

BMY	Bristol Myers	Biopharmaceutical Products	28	5.1	94.9B	59.90 No position	Possibly in a dbl top area	If bought sell at 53.90x
BA	Boeing	Aerospace, commercial jetliners, military systems	14	0.85	81B	238.12	Long at 132 10/04/16	210x
HL	Hecla Mining	Basic Materials	44	3.61	1.7B	5.20 Look for re-entry lower	No Position	A troubled long
FFIC	Flushing Financial	Bank Holding company Savings and loans	13	3.5	592Mln	26.70	19.10 bought 06/27/16	50 day m.a. at 27.45; sold below
HDGE	Bear ETF	Seems to stabilize at the \$ 8.50 level	NA	NA	176.8Mln	8.67	long 8.54 8/03/17	8.44x lowering stop loss
AA	Alcoa	Aluminum Processing and Technology	N/A	0.4	9.5B	42.37	21.15 originally bought 2/8/16	\$ If long sell Monday's opening
ENZ	Enzo Biochem	Life Sciences	NA	1.35	134M	11.10	Bought at 5.13 10/7/16	<i>Sold on Opening Monday 4/3/17 Sold 8.43</i>
BAC	Bank of America	Commercial Bank	10	2.02	165.3B	22.93	Bought at 15.42 9/30/16	23.60x stopped out 3/21/17

Rule 17B Attestations and Disclaimers

Princeton is paid \$ 1,500 per month from RMS Medical Products. The SITS contract calls for \$ 1,500 per month. Princeton had been engaged by Target Energy. No contract is currently in place. Princeton is paid \$ 2500 per month by Pressure Biosciences. Princeton was paid about 300,000 restricted shares of Leo Motors. Princeton is paid \$ 2,500 per month for International Star. Princeton is paid \$ 2,500 from Leo Motors.

Pursuant to the provisions of Rule 206 (4) of the Investment Advisers Act of 1940, readers should recognize that not all recommendations made in the future will be profitable or will equal the performance of any recommendations referred to in this Email issue. Princeton may buy or sell its free-trading shares in companies it represents at any time. Y means the writer has a position of 10,000 shares in the stock recommended.

CONTACT

Please Direct All Inquiries To:

Mike King
(702) 650-3000
mike@princetonresearch.com

Charles Moskowitz
(781) 826-8882

CAM@MoneyInfo-LLC.com

Princeton Research
3887 Pacific Street,
Las Vegas, Nevada 89121

Fax: (702) 697-8944

www.PrincetonResearch.com